ACHL:NSD-Achilles Therapeutics plc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 11.54

Change

0.00 (0.00)%

Market Cap

USD 0.47B

Volume

6.48K

Average Target Price

USD 21.20 (+83.71%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Company Website : http://www.achillestx.com

Address : 245 Hammersmith Road, London, United Kingdom, W6 8PW

Employees : 153

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

52 Week High : 18.95

Short Ratio : 14.45

52 Week Low : 11.42

Shorted Shares : 278,782

200 Day Moving Average : 14.00

Shorted Shares Previous Month : 273,904

50 Day Moving Average : 13.05

Short Percentage : 1.00%

Shares Held by Institutions : 46.62%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

N/A

 USD79.98B 133.51 104.16
REGN Regeneron Pharmaceuticals, Inc

N/A

 USD57.31B 15.31 11.96
BNTX BioNTech SE

N/A

 USD51.30B -99,999.99 31.95
VRTX Vertex Pharmaceuticals Incorpo..

N/A

 USD48.63B 17.91 12.34
ALXN Alexion Pharmaceuticals, Inc

N/A

 USD40.06B 58.65 41.96
BGNE BeiGene, Ltd

N/A

 USD29.61B N/A N/A
SGEN Seagen Inc

N/A

 USD28.37B 43.61 39.21
GMAB Genmab A/S

N/A

 USD28.05B 26.59 3.73
RPRX Royalty Pharma plc

N/A

 USD26.73B 22.60 15.75
ALNY Alnylam Pharmaceuticals, Inc

N/A

 USD20.79B N/A N/A

ETFs Containing ACHL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.47B 54% F 49% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.71 68% D+ 52% F
Price / Cash Flow Ratio -18.56 76% C 82% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -29.78% 76% C 31% F
Return on Invested Capital -23.20% 76% C 26% F
Return on Assets -17.13% 70% C- 21% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 14.45 11% F 4% F
Short Percent 9.50% 35% F 21% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.